🟢 Johnson & Johnson is trading 3.13% up today after favorable atrial-fibrillation treatment data

Johnson & Johnson is trading at $265.84, up +3.13%, with favorable atrial-fibrillation data cited as a positive contributor to shares’ sentiment.

• In its October 22 release, Johnson & Johnson reported VARIPURE’s 100% acute procedural success.
• In the Omny-IRE study, 82.5% of patients remained recurrence-free at 12 months under stringent monitoring.
• Healthcare rose 1.35% during the session, helping support the move amid broad market weakness.